<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04171661</url>
  </required_header>
  <id_info>
    <org_study_id>LOEX 019</org_study_id>
    <nct_id>NCT04171661</nct_id>
  </id_info>
  <brief_title>Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa</brief_title>
  <acronym>SASS</acronym>
  <official_title>SASS 3: Self-Assembled Skin Substitute (SASS) for the Treatment of Epidermolysis Bullosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single patient study. Patient diagnosed with dystrophic epidermolysis bullosa presenting
      chronic open wounds that are not responding to dressings, topical preparations
      (antimicrobials, antibiotics) and systemic agents (anti-inflammatory antibacterials). The
      Self-Assembled Skin Substitutes will be used to cover wounds.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">December 10, 2024</completion_date>
  <primary_completion_date type="Actual">December 24, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>n-of-one</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction in wound surface area</measure>
    <time_frame>2 weeks</time_frame>
    <description>Clinical assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft failure</measure>
    <time_frame>2 weeks</time_frame>
    <description>Clinical assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subsequent re-transplantation</measure>
    <time_frame>3 years</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (in weeks) to 50% reduction in the surface area of the wounds;</measure>
    <time_frame>3 years</time_frame>
    <description>Clinical assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (in weeks) to complete healing</measure>
    <time_frame>3 years</time_frame>
    <description>Clinical assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pain scores</measure>
    <time_frame>3 years</time_frame>
    <description>10 point visual analog scale where 0 is none and 10 the worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in itch scores where 0 is none and 10 the worst itch</measure>
    <time_frame>3 years</time_frame>
    <description>10 point scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Epidermolysis Bullosa Dystrophica</condition>
  <arm_group>
    <arm_group_label>SASS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SASS applied on chronic skin wounds as skin graft</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SASS</intervention_name>
    <description>SASS applied on chronic skin wounds as skin graft</description>
    <arm_group_label>SASS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        This clinical trial was custom designed for one patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dystrophic Epidermolysis Bullosa</keyword>
  <keyword>Recessive Dystrophic Epidermolysis Bullosa</keyword>
  <keyword>Tissue Engineering</keyword>
  <keyword>Skin Substitute</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

